
Agilon Health (AGL) Stock Forecast & Price Target
Agilon Health (AGL) Analyst Ratings
Bulls say
Agilon Health Inc. demonstrated strong financial growth in the fourth quarter, with total revenue increasing by 44.2% year-over-year, exceeding estimates by 0.2%. The company's membership in Medicare Advantage (MA) grew by 36% year-over-year, reaching 527,000 members, which supports revenue growth potential and reflects strong market demand. Additionally, the improved medical margin, despite missing estimates, hints at enhanced operational efficiency as the company gains access to timely hospital census data, setting a positive trajectory for future financial performance.
Bears say
Agilon Health's stock outlook is impacted negatively by its visibility issues, particularly in the second half of the year, which have led to unforeseen financial results, including an adjusted EBITDA of $(84.0) million in 4Q24, falling short of both consensus estimates and prior guidance. The company reported significantly lower medical margins, with actual figures of $0.6 million compared to expectations of $19.8 million, raising concerns about the sustainability of its revenue sources. Additionally, guidance for ACO REACH patients shows a decline of 20.5% to 12.9% quarter-over-quarter, indicating potential challenges in growth and profitability moving forward.
This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.
Agilon Health (AGL) Analyst Forecast & Price Prediction
Start investing in Agilon Health (AGL)
Order type
Buy in
Order amount
Est. shares
0 shares